Conference abstract

Urinary C-Peptide creatinine ratio is a measure of insulin secretion in diabetes patients in Cameroon

Pan African Medical Journal - Conference Proceedings. 2021:11(45).01 Feb 2021.
doi: 10.11604/pamj-cp.2021.11.45.969
Archived on: 01 Feb 2021
Contact the corresponding author
Keywords: UCPCR, C-peptide, insulin secretion, diabetes, Cameroon
Oral presentation

Urinary C-Peptide creatinine ratio is a measure of insulin secretion in diabetes patients in Cameroon

Jean-Claude Katte1,&, Virginie Poka2, Tim J McDonald1, Angus Jones1, Eugene Sobgnwi2,3

1College of Health and Medicine, University of Exeter Medical School, Exeter, United Kingdom, 2Department of Internal Medicine and Specialities, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, 3National Obesity Centre and Endocrinology and Metabolism Unit, Yaoundé Central Hospital, Yaoundé, Cameroon

&Corresponding author

Introduction: UCPCR has been shown to be a robust measure of insulin secretion in white Caucasian populations. We aimed to investigate the role of UCPCR as a surrogate measure of insulin secretion in patients with diabetes in a sub-Saharan Africa clinical setting. Methods: UCPCR was measured on separate days before and after a standard meal (mixed-meal tolerance test). Serum C-peptide was also measured before and after a standard 75g oral glucose tolerance test (OGTT) on a separate day. The primary outcome was the correlation between UCPCR and serum C-peptide levels. Results: a total of 14 subjects with diabetes and 14 healthy controls matched by age, sex and BMI were enrolled. Fasting and 2 hour post MMTT UCPCR correlated significantly with both serum C-peptide measurement (r = 0.61, p = 0.0197) and 120 OGTT serum C-peptide measurements (r = 0.74, p = 0.0006). Post-prandial UCPCR measurements after lunch and supper correlated significantly with 120 OGTT serum C-peptide levels with r =0.78, p= 0.0008 and r=0.80, p=0.0006 respectively. Conclusion: UCPCR therefore seems to be a satisfactory measure of insulin secretion in this group of diabetes patients. However further studies may be needed to investigate the use of UCPCR specifically in both type 1 and 2 diabetes sub-populations.